Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ERB-041 · 5 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| ERB-041 | DRUG | - |
Inclusion Criteria: * Surgical diagnosis of endometriosis within the last 10 years * Sexually active, nonpregnant, nonlactating women (18-45 years) with regular menstrual cycles who are willing to use non-hormonal contraception Exclusion Criteria: * Conditions requiring the use of chronic pain th...
ERB-041 is an investigational small molecule being studied for Crohn's Disease, endometriosis, dysmenorrhea, and pelvic pain. It has also been evaluated in healthy volunteers for cardiac safety and pharmacokinetic studies. The drug is in clinical development by Pfizer, Inc. and is not approved for any indication.
ERB-041 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The drug is an investigational small molecule in clinical development for gastrointestinal and women's health conditions.
ERB-041 has completed Phase 1 and Phase 2 clinical trials. The most advanced study was a Phase 2 trial in endometriosis, which has been completed. The drug remains investigational and is not FDA approved.
ERB-041 has been studied in four completed clinical trials. NCT00245947 evaluated the drug in active Crohn's Disease. NCT00316459 assessed cardiac repolarization effects in healthy subjects. NCT00318500 was a Phase 2 study in endometriosis symptoms. NCT00434187 evaluated multiple doses in healthy Japanese women.
ERB-041 is a distinct investigational compound developed by Pfizer. It is not known to be the same as any other marketed drug. The clinical trials listed under its name evaluate this specific small molecule for Crohn's Disease and endometriosis-related conditions.